MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

MDT

96.42

+0.17%↑

146.88

-0.15%↓

VEEV

230.71

-1.7%↓

HQY

83.52

-4.3%↓

PHR.US

16.41

-3.07%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.07 1.9

Buy Sell

Overview

Share price change

24h

Current

Min

1.03

Max

1.07

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+337.74% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	-9.2M 117M
Previous open	-0.83
Previous close	1.07

News Sentiment

By Acuity

10%

90%

10 / 370 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 sty 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 sty 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 sty 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 sty 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 sty 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 sty 2026, 21:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

12 sty 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 sty 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 sty 2026, 20:54 UTC

Earnings

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 sty 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 sty 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 sty 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 sty 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 sty 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 sty 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 sty 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 sty 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 sty 2026, 19:24 UTC

Acquisitions, Mergers, Takeovers

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 sty 2026, 19:22 UTC

Acquisitions, Mergers, Takeovers

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 sty 2026, 18:21 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 sty 2026, 18:20 UTC

Acquisitions, Mergers, Takeovers

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 sty 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 sty 2026, 18:16 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 sty 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 sty 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 sty 2026, 18:01 UTC

Acquisitions, Mergers, Takeovers

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 sty 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

337.74% upside

12 Months Forecast

Average 4.64 USD 337.74%

High 8 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

10 / 370 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.